The discovery of genetic mutations in CD33 and TREM2 associated with the risk of developing Alzheimer’s disease (AD) [1–4] has heightened the interest in defining microglia physiology and pathology in the context of disease. The gene discussed is CD33; the disease is Alzheimer disease.